نتائج البحث - Stefan Willmann

  • يعرض 1 - 14 نتائج من 14
تنقيح النتائج
  1. 1
    Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®

    Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim® حسب Stefan Willmann, Kirstin Thelen, Jörg Lippert

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

    First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development حسب Ashley Strougo, Thomas Eißing, Ashraf Yassen, Stefan Willmann, Meindert Danhof, Jan Freijer

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

    Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study حسب Heino Staß, Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Abhishek Gupta, Sybille Baumann

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models

    Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models حسب M. Vossen, Michael Sevestre, Christoph Niederalt, In‐Jin Jang, Stefan Willmann, Andrea N. Edginton

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data

    Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data حسب Karina Claassen, Kirstin Thelen, Katrin Coboeken, Thomas Gaub, Jörg Lippert, Karel Allegaert, Stefan Willmann

    منشور في 2015
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    A Generic Integrated Physiologically based Whole‐body Model of the Glucose‐Insulin‐Glucagon Regulatory System

    A Generic Integrated Physiologically based Whole‐body Model of the Glucose‐Insulin‐Glucagon Regulatory System حسب Stephan Schaller, Stefan Willmann, Jörg Lippert, L. Schaupp, Thomas R. Pieber, Andreas Schuppert, Thomas Eißing

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals

    Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals حسب Jan‐Frederik Schlender, Michaela Meyer, Kirstin Thelen, Markus Krauß, Stefan Willmann, Thomas Eißing, Ulrich Jaehde

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim

    A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim حسب Christoph Niederalt, Lars Kuepfer, Juri Solodenko, Thomas Eißing, Hans‐Ulrich Siegmund, Michael S. Block, Stefan Willmann, Jörg Lippert

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

    Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations حسب Stefan Willmann, Liping Zhang, Matthias Frede, Dagmar Kubitza, Wolfgang Mueck, Stephan Schmidt, Alexander Solms, Xiaoyu Yan, Dirk Garmann

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model

    Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model حسب Lars Kuepfer, Christoph Niederalt, Thomas Wendl, J‐F Schlender, Stefan Willmann, Jörg Lippert, Michael S. Block, Thomas Eißing, Donato Teutonico

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban

    Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban حسب Stefan Willmann, Corina Becker, Rolf Burghaus, Katrin Coboeken, Andrea N. Edginton, Jörg Lippert, Hans‐Ulrich Siegmund, Kirstin Thelen, Wolfgang Mück

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

    Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study حسب Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, Anthonie W.A. Lensing, Matthias Frede, Katrin Coboeken, Jan Stampfuss, Rolf Burghaus, Wolfgang Mück, Jörg Lippert

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

    PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients حسب Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian T. Lobmeyer, Anthonie W.A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard S. Geary, Sanjay Bhanot

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation

    Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation حسب Guy Young, Anthonie W.A. Lensing, Paul Monagle, Christoph Male, Kirstin Thelen, Stefan Willmann, Joseph S. Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Fanny Bajolle, Philip Connor, Hélène L. Hooimeijer, Marcela Torres, Anthony K.C. Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amédro, Jan Beyer‐Westendorf, Ida Martinelli, M. Patricia Massicotte, William T. Smith, Scott D. Berkowitz, Stephan Schmidt, Victoria Price, Martin H. Prins, Dagmar Kubitza

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: